GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Boston Scientific Corp (FRA:BSX) » Definitions » EV-to-EBITDA

Boston Scientific (FRA:BSX) EV-to-EBITDA

: 31.57 (As of Today)
View and export this data going back to 1992. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Boston Scientific's enterprise value is €100,974 Mil. Boston Scientific's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €3,199 Mil. Therefore, Boston Scientific's EV-to-EBITDA for today is 31.57.

The historical rank and industry rank for Boston Scientific's EV-to-EBITDA or its related term are showing as below:

FRA:BSX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -680.14   Med: 28.94   Max: 239.47
Current: 31.25

During the past 13 years, the highest EV-to-EBITDA of Boston Scientific was 239.47. The lowest was -680.14. And the median was 28.94.

FRA:BSX's EV-to-EBITDA is ranked worse than
81.76% of 488 companies
in the Medical Devices & Instruments industry
Industry Median: 14.625 vs FRA:BSX: 31.25

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-19), Boston Scientific's stock price is €64.00. Boston Scientific's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €0.993. Therefore, Boston Scientific's PE Ratio for today is 64.45.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Boston Scientific EV-to-EBITDA Historical Data

The historical data trend for Boston Scientific's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boston Scientific Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.69 41.80 27.12 27.18 27.16

Boston Scientific Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.18 28.58 30.13 25.90 27.16

Competitive Comparison

For the Medical Devices subindustry, Boston Scientific's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Boston Scientific EV-to-EBITDA Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Boston Scientific's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Boston Scientific's EV-to-EBITDA falls into.



Boston Scientific EV-to-EBITDA Calculation

Boston Scientific's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=100974.243/3198.681
=31.57

Boston Scientific's current Enterprise Value is €100,974 Mil.
Boston Scientific's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €3,199 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Boston Scientific  (FRA:BSX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Boston Scientific's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=64.00/0.993
=64.45

Boston Scientific's share price for today is €64.00.
Boston Scientific's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.993.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Boston Scientific EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Boston Scientific's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Boston Scientific (FRA:BSX) Business Description

Address
300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.